Neoadjuvant Triple Therapy for Resectable HCC

This study tests a triple combination treatment given before surgery for people with liver cancer (hepatocellular carcinoma, HCC) that could potentially be removed surgically. The treatment combines an anti-cancer drug, an immunotherapy drug, and a targeted therapy to try to shrink the tumor before surgery, making removal easier or possible. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with liver cancer (HCC) and have good liver function (Child-Pugh class A) - Your tumor is considered surgically resectable after specialist team review (BCLC stage A or B, single tumor over 5 cm or multiple tumors) - You have not received prior treatment for this cancer - Your blood counts and organ function are acceptable **You may NOT be eligible if:** - Your liver function is poor (Child-Pugh class B or worse) - Your cancer has spread outside the liver to distant organs - Your tumor cannot be measured on imaging - You have had previous liver surgery or organ transplant Talk to your doctor to see if this trial is right for you.